about
Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-discPrognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study.Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator.Haematopoietic stem cells improve cardiac function after infarction without permanent cardiac engraftment.Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy.Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports.Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overloadPeripartum cardiomyopathy: recent insights in its pathophysiology.Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II.The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure.Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion.Regulation of proangiogenic factor CCN1 in cardiac muscle: impact of ischemia, pressure overload, and neurohumoral activation.Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients.SH3P7/mAbp1 deficiency leads to tissue and behavioral abnormalities and impaired vesicle transport.Functional microRNA library screening identifies the hypoxamir miR-24 as a potent regulator of smooth muscle cell proliferation and vascularizationPeripartum cardiomyopathy: current management and future perspectivesEmerging translational approaches to target STAT3 signalling and its impact on vascular diseasePharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models.Many good reasons to have STAT3 in the heart.Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy.STAT3-mediated activation of myocardial capillary growth.MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathySurvival pathways in hypertrophy and heart failure: the gp130-STAT axis.Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathyInflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.Postpartum cardiomyopathy: a cardiac emergency for gynecologists, general practitioners, internists, pulmonologists, and cardiologists.The myocardial JAK/STAT pathway: from protection to failure.Article Commentary: Acute Heart Failure: Is it Peripartum Cardiomyopathy or Not?Management of peripartum cardiomyopathy.Reviewing peripartum cardiomyopathy: current state of knowledge.STAT3 and cardiac remodeling.Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy.Prolactin: a new therapeutic target in peripartum cardiomyopathy.Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy.Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.Towards a re-definition of 'cardiac hypertrophy' through a rational characterization of left ventricular phenotypes: a position paper of the Working Group 'Myocardial Function' of the ESC.16-kDa prolactin and bromocriptine in postpartum cardiomyopathy.Cardiovascular disorders in pregnancy: diagnosis and management.Peripartum cardiomyopathy: update 2012.STAT3 regulation of and by microRNAs in development and disease.
P50
Q28593396-E8EA5925-D4A5-4CE2-B3CB-B39F0DA5D848Q30372111-4A4CAB69-8E35-4AF4-AC62-BF58BB0AC20DQ33164921-B1899E87-9E85-4FC5-A1DE-E5272F8A8E1FQ33223226-B4C46E2C-16F9-4AB6-8EDD-CAA77E3F6C82Q33623465-AE8C4151-FE89-4C90-866C-295FB7677753Q33732241-FB20185B-D1DA-440B-9CD7-8F9DF8252E2AQ33886486-808CB604-8C67-4E01-9E4F-3D22491E9D12Q34013779-7897B208-827D-4851-B824-FD15312BC6B7Q34137476-E7F40C40-CA19-4A7A-97BE-640E54B88918Q34200352-8E43C5D0-9DD5-45EE-BC8E-49ECD8A4F188Q34300508-354B1E20-E8A6-4507-A791-DA8E9049E635Q34317397-FD73B9A9-4BF1-4E9B-A201-E198FC887F33Q34448604-260BE8BF-0567-44B9-87B8-E222BD9DBEBCQ34547405-83DD311B-51ED-4DBC-B164-339888264914Q34996380-6DB7C5D7-2F91-431A-A30C-D88A16EC47B5Q35578643-8279F109-B670-4C6B-9A97-DA46B98F99EFQ35580177-B0749544-3769-4698-A226-1C27324B5072Q35690375-02E16761-2AEA-4084-846B-F64B7D108FCDQ36166555-A6352778-EFD1-4CA3-9311-212EF3B0AA76Q36214915-2049F075-62B4-46DB-95C4-A562879CBDC9Q36228913-931FC42E-523C-466F-814B-213CDF4074E5Q36802746-DFD9C529-CFB1-426D-8533-A92296ABD0B6Q36961847-132B557D-3635-417A-82A1-63C2289B99F3Q37004855-4408A466-61F0-426A-B52B-B0DE4841924CQ37090971-4B7BACB6-A205-48F5-914F-3991EA376439Q37228864-096F3A8F-7499-47F1-B40C-A4A8631A4478Q37266843-6CA07910-A2F4-4C2E-9C09-03E46E4A216DQ37315379-E40AA645-483D-4523-810A-43C44FDB12A1Q37334543-BB2161B8-1217-4D9E-A44E-77AA0B120B8EQ37445871-6BBB6203-8572-4E91-9152-872B29E1EA3FQ37734934-B48DE41C-9368-4F6E-9664-91C99625DC6CQ37738585-5E92D277-7C8E-404D-AFDD-D23F4D9AEAECQ37775437-2FF34B72-2535-41CF-BA35-26D6AFB78EFFQ37776975-88B5F380-7557-4DA1-A466-9F7D551E1FBBQ37822215-2FB010B3-1D81-445F-B561-D9EA73BDA8BDQ37895014-81A22B01-B686-46FE-865E-6FEDA2D0A581Q38021361-168ACBB6-23DB-42A8-B351-DA29AE618043Q38128057-72C81487-C3F1-4576-935D-23D9F6137EF5Q38133260-324979FC-8F6A-426B-9D3C-8C5A16668EC7Q38140887-8C1CE66B-ACF2-46FA-BD93-57597CFD031C
P50
description
onderzoeker
@nl
name
Denise Hilfiker-Kleiner
@ast
Denise Hilfiker-Kleiner
@en
Denise Hilfiker-Kleiner
@es
Denise Hilfiker-Kleiner
@sl
type
label
Denise Hilfiker-Kleiner
@ast
Denise Hilfiker-Kleiner
@en
Denise Hilfiker-Kleiner
@es
Denise Hilfiker-Kleiner
@sl
prefLabel
Denise Hilfiker-Kleiner
@ast
Denise Hilfiker-Kleiner
@en
Denise Hilfiker-Kleiner
@es
Denise Hilfiker-Kleiner
@sl